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A B S T R A C T
Background: Critical limb ischemia (CLI) is the most advanced stage of peripheral arterial disease. CLI 
patients, compared to non-CLI, achieve worse treatment outcomes and generate higher costs. 
Aims: The aim of the study was to compare endothelial function and clinical outcomes in CLI and non-
-CLI patients after percutaneous transluminal angioplasty (PTA). 
Methods: In this prospective, follow-up study, 30 CLI patients and 40 non-CLI patients underwent 
PTA. Endothelial function was assessed based on flow mediated dilatation (FMD), reactive-hyperemia 
index (RHI), while the ankle-brachial index, toe-brachial index and the Rutherford scale were used for 
peripheral artery disease progression evaluation. The results were assessed before PTA, as well as 1, 3, 
6 and 12 months after the procedure.
Results: There were no differences at the baseline regarding to endothelial function between both 
groups. Neither FMD nor RHI changed after PTA in any of the groups, although there was a difference 
in median RHI value between CLI and non-CLI patients regarding the 1st and 6th month of the follow-up 
(RHI6–RHI1 = 0.08 in CLI and –0.15 in non-CLI; P = 0.01). The larger baseline intima-media thickness 
(IMT) in the CLI group allowed to predict a greater number of re-intervention (P = 0.01) and major ad-
verse event rates (P = 0.03). CLI patients presented larger decrease in the Rutherford scale compared 
to non-CLI (P <0.001).
Conclusions: Baseline IMT was predictive for re-interventions and major adverse event rates. Although 
neither of groups exhibited significant changes in endothelial function, we proved differences between 
them regarding to changes in RHI. 
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Peripheral artery disease (PAD) is characterized by ischemia 
in the lower limbs due to narrowing of the arteries because 
of atherosclerotic plaque accumulation [1]. Critical limb 
ischemia (CLI) is the most advanced stage of PAD associated 
with macro- and microcirculatory, as well as rheological 
disorders. The Inter‐Society Consensus for the Management 
of PAD estimates that 25% of patients diagnosed with CLI 
will die within 1 year and an additional 30% will undergo 
limb amputation [2]. CLI patients typically present a spec-
trum of symptoms including pain during rest, non-healing 
ulcers, and tissue necrosis with gangrene [3]. Limb revas-
cularization is considered the first line of treatment for CLI 
because it significantly reduces the rate of limb amputa-
tion and mortality [4, 5]. Comorbidities are more frequent 
in CLI patients, who require faster treatment access and 
more advanced procedural strategies. These facts make 
them more vulnerable to procedural complications [6–8]. 
Despite clinical differences between patients with CLI and 
those with limb claudication (non-CLI), they both exhibit 
805
Paweł Kaczmarczyk i wsp., Endothelial function after endovascular treatment
w w w . j o u r n a l s . v i a m e d i c a . p l / k a r d i o l o g i a _ p o l s k a
W H A T ’ S  N E W ?
In the majority of clinical studies related to peripheral arterial disease, critical limb ischemia (CLI) patients were analyzed to-
gether with non-critical limb ischemia (non-CLI) patients. Thus, it is unknown whether endothelial function after endovascular 
procedures changes in a similar way among CLI and non-CLI patients. To our knowledge, we are the first to investigate if there 
are any significant differences regarding endothelial function (flow mediated dilatation), intima-media thickness, or clinical 
outcomes separately in these 2 groups. It is suggested in the present study that CLI patients had better clinical response to 
revascularization than non-CLI patients (larger drop in the Rutherford scale, better increase in toe-brachial index [TBI]), however, 
there was no improvement in endothelial function after revascularization in either group.
endothelial dysfunction, the hallmark of atherosclerosis 
pathogenesis. In fact, endothelium-dependent vasodila-
tion is impaired in coronary artery disease patients [9, 10]. 
Interventions proven to reduce cardiovascular risk also 
reverse endothelial dysfunction and failure of the endothe-
lium to respond to therapy [11]. Endothelial dysfunction 
is also present in PAD patients. The loss of nitric oxide- 
-dependent regulation regarding flow in the lower limbs 
may worsen the vasoconstrictor effects of catecholamines 
and impair flow mediated dilatation (FMD), which, in con-
sequence, may worsen stenosis severity while increasing 
resistance to blood flow during exercise [12].
Understanding the heterogeneity of these two groups, 
we should expect many differences concerning clinical as-
pects between patients with claudication and critical limb 
ischemia, especially after revascularization. Nevertheless, in 
the majority of clinical studies related to PAD, CLI patients 
were analyzed together with non-CLI patients. It is not 
known whether endothelial function after endovascular pro-
cedures changes in a similar way in CLI and non-CLI patients. 
Therefore, here, we compared endothelial function and 
clinical outcomes in CLI and non-CLI patients after percu-




The study was conducted as a prospective, single-center 
follow-up evaluation. Patients with critical limb ischemia as 
well as those with stable PAD (Rutherford class from 2 to 3), 
due to iliac, femoropopliteal, or below–the-knee disease, 
were eligible for the study. Exclusion criteria were history of 
end-stage kidney disease, age above 85, and pain related 
to limb ischemia not allowing to maintain a horizontal 
position. Patients with incompressible tibial arteries were 
not eligible for the study.
All subjects provided their written and informed con-
sent before beginning the trial. The study complies with 
the 1964 Declaration of Helsinki and was approved by the 
local ethical committee. 
Endovascular procedures
Endovascular treatment was performed in a routine man-
ner. A 4 French (F) to 6F sheath was introduced into the 
artery and diagnostic angiography was performed. Each 
individual received 5 000 International Units of unfrac-
tionated heparin that was injected intra-arterially. The 
affected artery was treated using over-the-wire balloon 
catheters, and wherever necessary, nitinol self-expanding 
or expandable cobalt-chromium balloon stents. Post-in-
terventional therapy lasted 4 weeks and consisted of 
both aspirin (75 mg/d) and clopidogrel (75 mg/d). High-
dose statins (atorvastatin 40 mg to 80 mg or rosuvastatin 
20 mg to 40 mg) were initiated at baseline assessment for 
all patients and were maintained throughout the study, 
although compliance was not monitored. Follow-up visits 
were conducted 1, 6, and 12 months after the intervention. 
Successful angioplasty was defined by a final angiogram 
with residual stenosis of 30% or less, and post-intervention-
al ankle-brachial index (ABI) improvement of at least 0.1.
Assessment of FMD
The study was performed on the basis of current FMD as-
sessment guidelines [13]. Patients were examined in fasting 
state, in supine position. They were asked to refrain from 
smoking, as well as alcohol and caffeinated beverage con-
sumption in the 12 hours preceding the trial. All vasoactive 
drugs were discontinued 24 hours before the procedure. 
FMD was performed in a quiet, temperature-controlled 
room (21°C to 24°C). Measurements were performed on 
the dominant forearm. A B-mode brachial artery image 
was obtained using a 14-MHz linear-array transducer with 
the Siemens Accuson 2000 ultrasound. The longitudinal 
segment above the antecubital fossa was used to measure 
brachial artery diameter. 
At baseline, a 10-second clip was recorded to measure 
the baseline artery diameter. Then, a blood pressure cuff 
was inflated on the forearm to 40 mm Hg above systolic 
pressure for 5 minutes. Immediately after cuff deflation, 
maximal blood velocity was measured for 15 seconds to 
evaluate arterial flow. Next, a 120-second video clip of 
the brachial artery in B-mode was recorded to calculate 
the post-occlusion brachial artery diameter. Continuous 
analysis of changes in the artery diameter were performed 
during post-processing at the authors’ laboratory by means 
of a wall-tracking computer system developed by Zieliński 
et al. [14]. The maximal diameter (maximal FMD — % FMD) 
was obtained using a semi-automatic technique, operating 
on the basis of the two regions of interest (ROI), indicating 
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the anterior and posterior artery wall marked by the opera-
tor on the first frame of the ultrasound clip. The algorithm 
for tracking the borders of the arterial walls was based on 
the active contour method. 
Assessment of the Reactive Hyperemia Index (RHI)
Digital pulse amplitude was measured simultaneously with 
FMD in a fasting state and supine position using a portable 
appliance testing (PAT) device comprising a pneumatic 
plethysmograph measuring digital pulse volume changes 
(Endo-PAT2000, Itamar Medical, Caesarea, Israel) [15]. The 
digital pulse amplitude was acquired continually during the 
examination and digitally recorded to a laptop. Data were 
analyzed by a computerized algorithm (Itamar Medical), 
which automatically and operator-independently calcu-
lates Assessment of RHI.
Pulse Wave Analysis (PWA)
Arterial pulse waveform assessment of arterial stiffness was 
performed non-invasively with the commercially available 
SphygmoCor system (AtCor Medical). Peripheral pressure 
waveforms were recorded from the radial artery at the 
wrist, using applanation tonometry with a high-fidelity 
micromanometer. After 20 sequential waveforms had been 
acquired, a validated generalized transfer function was 
used to generate the corresponding central aortic pressure 
waveform. AP was defined as the maximal systolic pressure 
minus pressure at the inflection point. We measured pulse 
pressure (PP), augmentation index (AI), central augmen-
tation index (CAI), ejection duration (ED), subendocardial 
viability ration (SEVR), central augmentation pressure (CAP), 
CAP normalized for the heart rate of 75 beats per minute 
(CAP-HR75), stiffness index (SI), and reflection index (RI).
Assessment of lower limb ischemia
ABI was calculated with the patient in supine position. The 
highest systolic pressure of the anterior or posterior tibial 
artery was measured in each limb and then divided by the 
highest brachial artery pressure. The mean ABI value for the 
two legs was included in statistical analysis. Toe-brachial 
index [TBI] was also calculated with the patient in supine 
position. The systolic pressure on the big toe was obtained 
for each limb using a photoplethysmograph (Nicolet 
VasoGuard; VIASYS Healthcare, Madison, WI, USA), and 
was divided by the highest brachial artery pressure. Pain-
free walking distance and maximal walking distance were 
measured in each patient before PTA and at every follow-up 
visit using a treadmill exercise test.
Measurements of intima-media thickness (IMT)
To measure carotid IMT, ultrasonography of the common 
carotid artery, carotid bifurcation and internal carotid 
artery of the left and right carotid arteries was performed 
with a 7.5 MHz linear-array transducer (Siemens, Erlangen, 
Germany). On a longitudinal, two-dimensional ultrasound 
image of the carotid artery, the anterior and posterior walls 
of the carotid artery are displayed as two bright white lines 
separated by hypoechogenic space. The distance between 
the leading edge of the first, far wall bright line (lumen-in-
tima interface) and the leading edge of the second bright 
line (media-adventitia interface) indicates the IMT.
Follow-up of patients
All of the treated patients were followed at the Univer-
sity Hospital Angiology Outpatient Clinic for a period of 
12 months following the procedure. Endothelial function 
was assessed before as well as 1, 3, and 6 months after PTA 
based on FMD and the reactive-hyperemia index (RHI), 
while arterial stiffness was evaluated using arterial PWA. 
Clinical status was evaluated before as well as 1, 3, 6, and 
12 months following PTA using the ABI or TBI. The carotid 
artery was examined before and 1, 3, and 6 months after 
PTA via IMT measurement. The outcomes were analyzed 
separately. The primary outcome measures of the study 
were changes in endothelial function (FMD, RHI, arterial 
PWA), clinical status (ABI, TBI), and IMT after PTA. The 
secondary outcome measures were freedom from major 
adverse limb events (MALE; including occurrence of death, 
stroke, myocardial infarction, major amputation, and/or 
re-intervention). Secondary study endpoints were assessed 
as composite effect (MALE) and solely, all the outcomes 
separately. 
Statistical analysis
Categorical variables are presented as numbers and per-
centages. Continuous variables are expressed as mean 
(standard deviation, [SD]) or median (lower quartile [Q1] 
— upper quartile [Q3]), where applicable. Normality was 
assessed via the Shapiro-Wilk test. Equality of variance was 
evaluated using the Levene’s test. Differences between 
the two groups were compared using the Student’s or 
Welch’s t-test, depending on the equality of variances for 
normally distributed variables. The Mann-Whitney U test 
was applied for non-normally distributed continuous vari-
ables. Categorical variables were compared with the Pear-
son’s chi-squared or Fisher’s exact tests if 20% of cells had an 
expected count of less than 5 (Monte Carlo simulation for 
Fisher’s test using tables of higher dimensions than 2 × 2). 
The Wilcoxon matched pair test was used for the compari-
son of two dependent samples. Friedman’s non-parametric 
ANOVA was used to compare repeated measures of more 
than two groups and between the groups with more than 
two measurements. Re-intervention rates and MALE rates 
in the CLI and non-CLI groups were compared using the 
log-rank test. Kaplan-Meier estimate curves were generated 
for MALEs and re-interventions according to the CLI sta-
tus. MALEs was defined as a composite clinical endpoint in-
cluding: occurrence of death, stroke, myocardial infarction, 
major amputation, and/or re-intervention. For comparison 
of relative changes in endothelial and clinical parameters 
between measurements at given time periods after PTA 
in the CLI and non-CLI groups, the Benjamini–Hochberg 
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procedure was used to adjust the P-value [16]. Spearman 
correlation coefficient was calculated for comparison be-
tween selected indices. A P-value of <0.05 was considered 
statistically significant. STATISTICA for Windows Release 
10 (Statsoft Inc., 2011) was used for data analysis.
RESULTS
Patient characteristics
Clinical characteristics of the patients included in the 
present study are shown in Table 1. The mean age of the 
CLI patients was 65.6 (7.5) years, while for non-CLI patients 
this totaled 67 (7) years. There were no differences in age 
between these two groups.
There were also no differences in pharmacological 
treatment or family medical history between the groups 
(Table 1). At the time of admission, less than 20% of patients 
were on statins, anti-platelet, or angiotensin converting 
enzyme inhibitor/ angiotensin receptor blockers-based 
therapy. After PTA, all patients were prescribed treatment 
based on aspirin with clopidogrel and high-doses of 
statins. Kidney failure was defined when glomerular filtra-
tion rate was less than 60 ml/min/1.73 m2. Blood pressure 
higher than 140/90 mm Hg was defined as abnormal. Since 
we did not measure in this study serum glucose and LDL 
levels, we had to accept diagnoses of diabetes and hyper-
cholesterolemia from patients’ medical history.
Considering the observational period, the mean length 
of the follow-up was 406.1 (209.7) days in the CLI group and 
471.7 (179.2) days in the non-CLI group (P = 0.17). Then, the 
follow-up period in both groups was limited to 12 months 
in order to objectify the comparative analysis of follow-up 
results. During the 12-month follow-up, there were no 
amputations in the non-CLI group, but 2 amputations in 
the CLI group (6.7%). There were 9 (30%) re-interventions in 
the CLI group and 4 (10%) in the non-CLI group (P = 0.03). 
During the follow-up period, 1 patient (2.5%) from the 
non-CLI group died, while no cases of death were noted 
in the CLI group during that time. Summarizing, there 
were 11 (36.7%) MALEs in the CLI group and 5 (12.5%) in 
the non-CLI group (P = 0.02). CLI and non-CLI groups also 
displayed differences in outcomes based on Kaplan-Meier 
survival analysis for MALE and re-interventions (Figure 1). 
Walking distance
Pain-free walking distance and maximal walking distance 
improved only in the non-CLI group (P = 0.02 and P = 0.01, 
respectively), however, there were no differences between 
the groups (P = 0.13 and P = 0.11, respectively; Table 2).
IMT
The relationship between clinical outcomes and 
baseline IMT 
The IMT value >0.9 mm was found in 36 patients (50.7%) 
from the overall group. The re-interventions occurred 
in 10 patients with IMT >0.9 mm out of 13 found in the 
whole group (76.9%), while considering MALEs there were 
11 patients with IMT >0.9 mm out of 16 found in the overall 
group (68.7%). The relationship between baseline IMT and 
clinical outcomes showed that CLI patients with higher 
initial mean IMT (thicker than 0.9 mm) value experienced 
the need for a larger number of re-interventions (r = 0.45; 
P = 0.01) and larger number of MALEs (r = 0.45; P = 0.01). 
Table 1. Baseline patient characteristics
Variables Number of individuals, n (%) P-value
CLI (n = 30) Non-CLI (n = 40)
Age, years 65.6 (7.5) 67.0 (7.0) 0.57
Gender, males 24 (80) 31 (77.5) 0.8






Hypertension 18 (60) 32 (80) 0.06
Dyslipidemia 15 (50) 19 (47.5) 0.83






Coronary artery disease 11 (36.7) 15 (37.5) 0.94
Myocardial infarction 3 (10) 7 (17.5) 0.37
Kidney failure (GFR <60 ml/min/1.73 m2) 3 (10) 1 (2.5) 0.18


























Data are expressed as mean (SD), median (IQR) and numbers (percentages). 
Abbreviations: ACEIs, angiotensin converting enzyme inhibitor; ARBs, angiotensin receptor blockers; Ca-blockers, calcium channel blockers; CLI, critical limb ischemia; GFR, 
glomerular filtration rate
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Figure 1. A. Kaplan-Meier survival curves according to critical limb ischemia (CLI) and non-CLI status for major adverse lower limb events.  
B. Kaplan-Meier survival curves according to CLI and non-CLI status for re-interventions
Abbreviations: MALE, major  adverse  limb events
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Table 2. Changes of endothelial function parameters in critical limb ischemia (CLI) and non-CLI patients during the 6-month follow-up period 
following angioplasty
Variable CLI P-value Non-CLI P-value P-valuea
At baseline 1 month 6 months At baseline 1 month 6 months
FMD 3.0 (1.7–4.7) 5.2 (3.3–6.4) 2.9 (1.9–5.3) 0.16 4.4 (2.1–6.6) 3.9 (2.6–6.5) 2.4 (1.3–4.4) 0.08 0.26
PP 66 (56–76) 63 (56–80) 72 (56–80) 0.88 71 (69–75) 66 (58–78) 62 (53–70) 0.4 0.74
AI 100.5 (88–115) 92.5 (82–107) 98 (83–105) 0.65 94 (85–110) 94 (87–109) 93.5 (88–99.5) 0.23 0.74
Central AI 149 (138–178) 148 (130–165) 151 (133–170) 0.79 156 (135–172) 163 (142–168) 148 (138–158.7) 0.12 0.85
ED 323 (289–337) 322 (294–342) 336 (294–346) 0.6 308 (290–330) 305 (292–329) 314.5 (301.7–330) 0.58 0.81
SEVR 154 (133–171) 145 (118–156) 148 (131–160) 0.61 144.5 (132–165.5) 149 (126–160) 144.5 (133–162.5) 0.89 0.99
CAP 17 (13.5–26) 18 (14–23.5) 18 (12–27) 0.91 17 (13–27) 20 (13–23) 15.5 (12.2–21.5) 0.25 0.89
CAP HR75 17 (11.5–19.5) 14.5 (13.2–19.5) 14 (10–20.5) 0.77 16 (14–21) 16 (14–21) 13 (11–17.2) 0.03 0.61
SI 20 (20–20) 20 (19–20) 20 (20–20) 0.93 20 (18–20) 20 (17–20) 20 (20–20) 0.66 0.15
RI 100 (100–100) 100 (97–100) 100 (100–100) 0.94 100 (94–100) 100 (80.1–100) 100 (100–100) 0.58 0.07
RHI 1.46 (1.19–1.81) 1.37 (1.08–1.62) 1.44 (1.16–1.98) 0.66 1.59 (1.22–2.26) 1.68 (1.32–2.22)* 1.46 (1.32–1.73) 0.16 0.69
PFWD, m 50 (8.75–200) 100 (50–200) 125 (82.5–200) 0.39 50 (27.5–100) 200 (47.5–500) 100 (35–400) 0.02 0.13
MWD, m 100 (10–250) 200 (70–200) 200 (87.5–300) 0.27 100 (30–150) 300 (50–500) 150 (82.5–500) 0.01 0.11
SBP, mm Hg 143.8 (18.2) 145.6 (16.3) 149.4 (18.6) 0.56 150 (14.8) 146 (19.3) 142.2 (16.7) 0.18 0.35
DBP, mm Hg 77.1 (9.2) 78.1 (7.6) 79.8 (7.0) 0.52 81.9 (6.8)b 80.2 (7.0) 79.1 (10.5) 0.41 0.1
IMT, mm 0.94 (0.3) — 0.91 (0.26) 0.055 0.97 (0.29) — 0.94 (0.26) 0.23 0.88
Data are expressed as mean (SD) and median (IQR).
aComparison between CLI and non-CLI with ANOVA Friedman’s test for two groups with repeated measurements (2-way repeated measures ANOVA test).
bP <0.05 when comparing particular indices at corresponding time points in the CLI and non-CLI groups.
Abbreviations: AI, coronary augmentation index; CAP, central augmentation pressure; CAP HR75, CAP normalized for the heart rate of 75 beats per minute; DBP, diastolic blo-
od pressure; ED, ejection duration; FMD, flow mediated dilatation; IMT, intima-media thickness; MWD, maximal walking distance; PFWD, pain-free walking distance; PP, pulse 
pressure; RHI, reactive-hyperemia index; RI, reflection index; SBP, systolic blood pressure; SEVR, subendocardial viability ratio; SI, stiffness index
Clinical outcomes 
Changes in Rutherford scale and TBI after PTA 
in CLI and non-CLI patients
Clinical outcomes assessed as the Rutherford grade re-
vealed that during the follow-up, the Rutherford grade 
decreased significantly in the CLI group and did not change 
in the non-CLI (Figure 2). TBI did not change at the following 
time points in the CLI and non-CLI groups, and did not differ 
between either of the groups (Figure 2).
Endothelial function
Changes in FMD after PTA in CLI and non-CLI 
patients
The FMD measurements did not change during the follow-
ing time points of the observational period in the CLI or 
non-CLI group (P = 0.16 and P = 0.08). FMD response to PTA 
did not differ between these groups (Table 2). Analyzing 
the measurements at given time points following PTA, we 
noted no significant differences (Figure 2).
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Changes in RHI after PTA in CLI and non-CLI 
patients
Similarly to FMD, RHI did not change during the follow-up 
period in the CLI or non-CLI groups (Table 2). In contrast 
to FMD, calculating relative changes between measure-
ments at given time points following PTA, changes in 
RHI (∆RHI) were negligible in the CLI and non-CLI groups 
(Table 2, 3 and Figure 2). However, ∆RHI 1–6 differed be-
tween the CLI and non-CLI groups (P = 0.01).
Changes in PWA after PTA in CLI and non-CLI 
patients
No significant changes were observed for PWA indices 
when considering the following time points in the CLI and 
non-CLI group, or comparing both groups (Table 2). 
DISCUSSION
In the present study, we compared changes within en-
dothelial function and clinical outcome after PTA in a group 
of 30 patients with CLI symptoms and a group of 40 patients 
with limb claudication. With regard to the clinical aspects 
of our study, we noted a significant increase in walking 
distance after PTA among patients with limb claudication as 
well as improved wound healing in the CLI patients. In the 
latter group, the Rutherford scale improved considerably 
(P <0.001), and thus improvement remained longer, than 
in non-CLI patients.
We also used ABI and TBI to improve assessment regard-
ing the clinical status of PAD patients. In CLI patients, we 
focused on TBI since it has been shown to present better 
accuracy in CLI diagnosis than ABI [7–9]. In this study, the 
Figure 2. A. Rutherford grade in critical limb ischemia (CLI) and non-CLI patients at selected time points. B. Toe-brachial index  in CLI and 
non-CLI patients at selected time points. C. Flow mediated dilatation in CLI and non-CLI patients at selected time points. D. Reactive-hy-
peremia index in CLI and non-CLI patients at selected time points. The horizontal line in the box indicates the median, the boxes indicate 
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Table 3. Comparison of relative changes in endothelial and clinical parameters between measurements at given time periods after percuta-
neous transluminal angioplasty in the critical limb ischemia (CLI) and non-CLI groups
Variable CLI




∆FMD 0–1 1.5 (–1.74–3.55) 0.82 (–2.06–2.95) 0.75 0.91
∆FMD 0–6 0 (0–0.29) 0 (0–0.31) 0.3 0.9
∆FMD 1–6 –5.11 (–6.43– –2.04) –4.18 (–6.45– –3.31) 0.91 0.91
∆RHI 0–1 –0.07 (–0.31–0.17) 0.1 (–0.55–0.75) 0.31 0.31
∆RHI 0–6 0.18 (–0.45–0.41) –0.18 (–0.91–0.24) 0.14 0.21
∆RHI 1–6 0.08 (–0.13–0.58) –0.15 (–0.5–0.01) 0.01 0.03
∆ABI 0–6 0.12 (–0.17–0.23) 0.09 (–0.005–0.25) 0.66 0.79
∆ABI 0–12 –0.1 (–0.31–0.12) 0.005 (–0.1–0.14) 0.2 0.4
∆ABI 1–6 –0.07 (–0.16–0.06) 0.05 (–0.07–0.14) 0.03 0.12
∆ABI 1–12 –0.11 (–0.2–0.01) –0.04 (–0.26–0.12) 0.79 0.79
∆TBI 0–6 0.09 (–0.08–0.16) 0.005 (–0.19–0.19) 0.69 0.75
∆TBI 0–12 –0.04 (–0.24– –0.003) 0.02 (–0.16–0.12) 0.25 0.62
∆TBI 1–6 0.01 (–0.05–0.04) –0.04 (–0.08–0.008) 0.31 0.62
∆TBI 1–12 –0.03 (–0.13–0.09) –0.05 (–0.19–0.11) 0.75 0.75
∆Rutherford 0–6 –3 (–3.25– –1.75) –2 (–2– –1) <0.001 <0.007
∆Rutherford 0–12 –3 (–4– –2) –2 (–2– –1) <0.001 <0.001
∆Rutherford 1–6 0 (–3–0) 0 (0–1) 0.004 0.004
∆Rutherford 1–12 –1 (–4–0) 0 (–1–1) <0.001 <0.001
∆IMT 0–6 –0.07 (–0.42– –0.002) –0.03 (–0.17–0.06) 0.07 0.07
Data are expressed as median (IQR); 0–1 indicates the difference between the first month following the procedure and baseline value; 0–6 — the difference between the sixth 
month following the procedure and baseline value; 0–12 — the difference between the twelfth month following the procedure and baseline value.
aP — after adjustment by Benjamini–Hochberg procedure.
Abbreviations: ABI, ankle-brachial index; TBI, toe-brachial index; other: see Table 1 and 2
post-procedural increase in ABI and TBI was observed 
both in the CLI and non-CLI groups. However, based on 
the analyzed results, the TBI was the factor that improved 
predominantly in CLI patients. In contrast with non-CLI 
patients, the improvement in CLI group was observed till 
the end of the follow-up.
Another interesting finding of this study was achieved 
by the analysis of IMT. We noted that CLI patients with 
higher mean baseline IMT had significantly poorer clinical 
outcomes (P = 0.01 for re-interventions and P = 0.03 for 
major adverse events). Indeed, IMT has significant predic-
tive value in assessing the risk of cardiovascular and cere-
brovascular events [12, 17–20]. In several studies, a strong 
correlation has been shown between increased IMT and 
peripheral artery occlusive disease [21–23]. It is presumed 
that by reducing the IMT, we reduce vessel stiffness, which 
may directly translate into improved claudication distance. 
Improved blood supply to the arteries of the lower limbs 
(increased blood flow to the peripheral parts of the lower 
limbs), directly translates into a longer claudication dis-
tance and increased patient mobility (a kind of walking 
training), which has been shown to reduce arterial stiffness 
and improve endothelial function. 
Endothelial function in CLI and non-CLI patients was 
measured on the basis of FMD and RHI measurements, 
which are well-established methods used in the assessment 
of endothelial dysfunction in patients with cardiovascular 
disease in conduit and resistance vessels, respectively [24]. 
In previous studies using FMD and RHI, it has been shown 
that the FMD response and RHI score reflect endothelial 
status and, to some degree, NO-bioavailability [18]. The 
RHI correlates with the measurement of endothelial vaso-
dilator function in the coronary arteries and with brachial 
FMD, although it has been suggested in other studies that 
FMD and RHI do not always correlate [25, 26]. Nevertheless, 
both endothelial function tests significantly predicted 
cardiovascular events [27, 28].
In the present work, neither FMD nor RHI signifi-
cantly improved during the follow-up in CLI or non-CLI 
patients. ∆FMD improved during the first month of 
observation in both groups, however, this improvement 
did not sustain as ∆FMD decreased between the first and 
sixth month following PTA. Similarly in RHI measurements, 
∆RHI displayed only transient improvement after the first 
month of PTA in CLI patients, and there were no significant 
differences between the first and sixth month in CLI and 
non-CLI group. 
These results indicate that improvement of endothelial 
function after revascularization was transient and lasted 
only up to the first month following PTA. After that time, 
endothelial function deteriorated, even though patients 
displayed clinical benefits from revascularization. 
Some previous reports confirmed the beneficial effects 
of peripheral artery revascularization on all-cause and 
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cardiovascular mortality as well as improvement of global 
endothelial [29–32]. On the other hand, Budzyński et al. 
[33] reported that superficial femoral artery (SFA) stenting 
and classical pharmacotherapy did not significantly mod-
ify systemic endothelial function, as assessed by FMD in 
patients with adequately controlled individual risk factors 
of atherosclerosis. In contrast, among patients who did 
not reach treatment targets before SFA stenting, in those 
who underwent intensification of pharmacotherapy prior 
to the endovascular procedure, noticeable improvement 
in endothelial function markers (FMD, IMT) was observed 
within 3–6 months of observation.
The results of the present work suggest that neither PTA 
nor newly introduced pharmacological treatment (aspirin, 
clopidogrel, statin) had significant and sustained impact on 
post-PTA endothelial function. This may be due to several 
reasons. Firstly, we did not record compliance with the new-
ly prescribed medications. We did not evaluate the level of 
control of patients’ comorbidities, such as hypertension or 
diabetes. Furthermore, the follow-up period might have 
been too short, since most of the CLI patients required sev-
eral months for the wounds to heal (up to 6 months). Based 
on the study, we may presume that a possible  positive 
response of endothelial function to PTA and treatment was 
too weak, so  intensification of pharmacological treat-
ment would be needed to afford sustained improvement 
of endothelial function and more sustained benefits in PAD 
patients.  Accordingly, endothelial-guided therapy may 
provide a tool to improve the efficacy of vascular pharma-
cotherapy that may be greater in non-CLI then CLI patients 
given the advanced disease in the latter group [34, 35].
Study limitations
The major study limitation of the present work was a rel-
atively low number of patients included in the study. Fur-
thermore, a modification of treatment (all patients were 
treated with statin, aspirin, and clopidogrel after PTA), 
improvement of patient compliance, modification of life-
style (e.g. reduction in the number of cigarettes smoked, 
quitting smoking, or increasing physical activity) could also 
improve endothelial function after PTA, thus, it is difficult 
to interpret if endothelial function changes reported here 
were strictly related to endovascular procedure or could 
be the consequence of lifestyle changes, or medications. 
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